| abstract |
An antibody against solubilized glypican 3 (GPC3) whereby solubilized GPC3 in a subject sample can be detected. By detecting solubilized GPC3 in a subject sample in vitro, it can be judged whether or not the subject suffers from caner, in particular, liver cancer. Further, a cell-disrupting agent or an anticancer agent containing this antibody against GPC which can disrupt cells, in particular, cancer cells. |